B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 This proposed transaction further diversifies Zimm ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Viking Therapeutics Inc (VKTX) reports significant R&D progress and financial bolstering despite increased losses and ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...